Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

Inclusion Criteria: * Diagnosis of cancer * Chronic nausea over the past 4 weeks * Average nausea numeric rating scale \>= 4/10 over the past 5 days at screening * Outpatient at MD Anderson Cancer Center * Karnofsky performance status \>= 50% * Age 18 or older * Able to complete study assessments, including keeping a daily diary Exclusion Criteria: * Delirium (i.e. Memorial Delirium Rating Scale \> 13) * Clinical evidence of bowel obstruction at the time of study enrollment * Expected to use other 5HT3 antagonists or NK1 antagonists for prophylaxis during the study * Continuation of over-the-counter therapies for nausea and/or vomiting during the study * On cytotoxic chemotherapy in the high/moderate/low emetogenic risk categories or oral antineoplastic agents in the high or moderate emetogenic risk categories according to the latest National Comprehensive Cancer Network (NCCN) guideline within 2 weeks of study enrollment * On scheduled potent CYP3A4 inducers at the time of study enrollment (avasimibe, carbamazepine, phenytoin, rifampin, efavirenz, nevirapine, barbiturates, systemic glucocorticoids, modafinil, oxcarbazine, phenobarbital, pioglitazone, rifabutin, St. John's wort, troglitazone) * On scheduled CYP3A4 substrates with narrow safety range at the time of study enrollment (alfentanil, cyclosporine, dihydroergotamine, ergotamine, pimozide, quinidine, sirolimus, tacrolimus) * On scheduled strong or moderate CYP3A4 inhibitors (boceprevir, clarithromycin, conivaptan, …